Xeris Biopharma Files Patent Infringement Lawsuit Against Generic Competitors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy XERS?
Source: Businesswire
- Patent Infringement Lawsuit: Xeris Biopharma and its subsidiaries have filed a patent infringement lawsuit against Torrent Pharmaceuticals and Somerset Therapeutics to prevent them from manufacturing and selling a generic version of Recorlev®, aiming to protect its patents until March 2040.
- Legal Basis: The lawsuit is filed under the Hatch-Waxman Act, with Xeris seeking an injunction to stop ANDA filers from producing, using, or selling generics before patent expiration, demonstrating the company's strong intent to protect its intellectual property.
- Market Impact: Xeris's CEO expressed confidence in the quality of the intellectual property for Recorlev, indicating that this lawsuit is not only a firm response to competitors but may also influence the sales and pricing strategies of Recorlev in the market.
- Future Outlook: Xeris anticipates receiving additional Notice Letters from ANDA filers, indicating interest in generic versions of Recorlev, and plans to continue enforcing its intellectual property rights to maintain its competitive edge in the biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XERS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XERS
Wall Street analysts forecast XERS stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.120
Low
9.00
Averages
9.67
High
10.00
Current: 6.120
Low
9.00
Averages
9.67
High
10.00
About XERS
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on improving patient lives by developing and commercializing products across a range of therapies. It has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. It also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. It is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Xeris Pharmaceuticals Q4 Earnings Beat Expectations
- Earnings Beat: Xeris Pharmaceuticals reported a Q4 GAAP EPS of $0.06, exceeding expectations by $0.03, indicating ongoing improvements in profitability that bolster investor confidence.
- Significant Revenue Growth: The company achieved Q4 revenue of $85.81 million, a 42.8% year-over-year increase, although it fell short of the $85.99 million consensus, reflecting strong demand for its products and increasing market recognition.
- 2026 Revenue Guidance: Xeris provided a revenue guidance range of $375 million to $390 million for 2026, which is below the $368 million consensus, yet demonstrates the company's confidence in future growth, potentially attracting long-term investor interest.
- Optimistic Market Outlook: Despite facing a rating downgrade, Xeris Pharmaceuticals shows a positive market outlook with strong momentum for its Recorlev product and pipeline opportunities, which may support future performance growth.
See More
Xeris Biopharma Projects 2026 Revenue Guidance Above Consensus
- Optimistic Revenue Guidance: Xeris Biopharma projects 2026 revenue between $375 million and $390 million, exceeding the market consensus of $368 million, reflecting the company's confidence in future growth.
- Improved Profitability: The company reported a non-GAAP EPS of $0.06 for Q4, compared to a loss of $0.03 in the same period last year, indicating a significant enhancement in profitability that boosts investor confidence.
- Strong Recorlev Sales: Sales of Recorlev (levoketoconazole) surged 100% year-over-year to approximately $45.3 million, becoming the company's best-selling therapy and driving overall revenue growth of 43% year-over-year.
- Healthy Cash Position: As of the end of 2025, the company had approximately $111 million in cash and cash equivalents, a significant increase from $71.6 million on December 31, 2026, providing ample funding for future investments.
See More
Xeris Biopharma Reports Record Revenue Growth and Profitability in Q4 2025
- Financial Self-Sustainability: Xeris Biopharma achieved total revenue of $85.8 million in Q4 2025, reflecting a 43% year-over-year growth, with full-year revenue reaching $291.8 million, marking a 44% increase and indicating the company's ability to self-fund its strategy and future growth.
- Recorlev Growth Engine: Revenue from Recorlev hit $45.3 million in Q4, with over 100% growth for the year and a doubling of the patient base to approximately 700, as the commercial team was nearly doubled in January to accelerate adoption, showcasing strong market demand and expansion potential.
- Positive Future Outlook: Management projects total revenue for 2026 to be between $375 million and $390 million, representing over 30% growth at the midpoint compared to 2025, while planning to increase R&D spending by $25 million and SG&A by $45 million to support the clinical advancement of XP-8121.
- Patent Protection Measures: The company has filed a patent infringement lawsuit to protect Recorlev, holding four Orange Book-listed patents valid until 2040, demonstrating a commitment to safeguarding its intellectual property and reducing potential competitive risks.
See More
Wall Street's First Trading Day of March Outlook
- Middle East Impact: The U.S.-Israeli attack on Iran is likely to ripple through financial markets, with oil prices rising due to geopolitical risk premiums, as Brent crude has surged from the low $60s to around $73, indicating potential for further volatility.
- CrowdStrike Earnings Preview: CrowdStrike is set to report its quarterly results after Tuesday's close, with Wall Street expecting fiscal 2026 Q4 revenue of $1.3 billion and EPS of $1.10, providing CEO George Kurtz an opportunity to highlight the cybersecurity sector's unique position amidst AI disruption fears.
- Broadcom Earnings Expectations: Broadcom will release its earnings on Wednesday, with anticipated fiscal 2026 Q1 revenue of $19.14 billion and EPS of $2.02, as market sentiment remains optimistic about AI chip demand despite concerns over potential disruptions to infrastructure software.
- Costco Quarterly Report: Costco is expected to report its fiscal 2026 Q2 results after Thursday's close, with projected revenue of $69.22 billion and EPS of $4.56, as management will address consumer spending trends and membership renewal rates amid high price pressures.
See More
Xeris Biopharma Shares Drop Amid Patent Infringement Lawsuit
- Patent Lawsuit Impact: Xeris Biopharma Holdings, Inc. has filed a patent infringement lawsuit against Torrent Pharmaceuticals and Somerset Therapeutics to protect its drug Recorlev, demonstrating the company's commitment to safeguarding its intellectual property rights.
- Stock Price Volatility: Despite a notable 61.30% increase in stock price over the past year, XERS shares are currently trading at $6.01, which is 12.6%, 15.9%, and 20.2% below the 20-day, 50-day, and 100-day moving averages, indicating a bearish sentiment in the short term.
- Technical Indicator Analysis: The current Relative Strength Index (RSI) stands at 42.31, indicating a lack of strong momentum, while the MACD being below the signal line further confirms bearish trends, suggesting that investors should remain cautious about potential shifts in stock trajectory.
- Earnings Outlook: Xeris Biopharma is set to report earnings on March 2, 2026, with an estimated EPS of 4 cents and revenue of $84.17 million, reflecting a positive growth outlook despite the challenges posed by the patent lawsuit.
See More
Xeris Pharmaceuticals to Announce Q4 Earnings on March 2
- Earnings Announcement: Xeris Pharmaceuticals is set to release its Q4 2023 earnings report on March 2 before market open, with a consensus EPS estimate of $0.04, reflecting a significant year-over-year increase of 233.3%, indicating a notable improvement in profitability.
- Revenue Growth Expectations: Analysts forecast that Xeris will achieve $86 million in revenue for Q4, representing a 43.1% year-over-year growth, which highlights the company's strong performance in market demand and product sales, potentially boosting investor confidence.
- Pipeline Opportunities: Xeris Biopharma shows strong momentum with its Recorlev product, indicating potential in drug development and market expansion, which could support future revenue growth.
- Rating Downgrade Impact: Despite the strong growth outlook, Xeris Biopharma's rating has been downgraded, reflecting market caution regarding the company's future performance, which may exert short-term pressure on its stock price.
See More
Xeris Pharmaceuticals Q4 Earnings Beat Expectations
- Earnings Beat: Xeris Pharmaceuticals reported a Q4 GAAP EPS of $0.06, exceeding expectations by $0.03, indicating ongoing improvements in profitability that bolster investor confidence.
- Significant Revenue Growth: The company achieved Q4 revenue of $85.81 million, a 42.8% year-over-year increase, although it fell short of the $85.99 million consensus, reflecting strong demand for its products and increasing market recognition.
- 2026 Revenue Guidance: Xeris provided a revenue guidance range of $375 million to $390 million for 2026, which is below the $368 million consensus, yet demonstrates the company's confidence in future growth, potentially attracting long-term investor interest.
- Optimistic Market Outlook: Despite facing a rating downgrade, Xeris Pharmaceuticals shows a positive market outlook with strong momentum for its Recorlev product and pipeline opportunities, which may support future performance growth.
See More
Xeris Biopharma Projects 2026 Revenue Guidance Above Consensus
- Optimistic Revenue Guidance: Xeris Biopharma projects 2026 revenue between $375 million and $390 million, exceeding the market consensus of $368 million, reflecting the company's confidence in future growth.
- Improved Profitability: The company reported a non-GAAP EPS of $0.06 for Q4, compared to a loss of $0.03 in the same period last year, indicating a significant enhancement in profitability that boosts investor confidence.
- Strong Recorlev Sales: Sales of Recorlev (levoketoconazole) surged 100% year-over-year to approximately $45.3 million, becoming the company's best-selling therapy and driving overall revenue growth of 43% year-over-year.
- Healthy Cash Position: As of the end of 2025, the company had approximately $111 million in cash and cash equivalents, a significant increase from $71.6 million on December 31, 2026, providing ample funding for future investments.
See More
Xeris Biopharma Reports Record Revenue Growth and Profitability in Q4 2025
- Financial Self-Sustainability: Xeris Biopharma achieved total revenue of $85.8 million in Q4 2025, reflecting a 43% year-over-year growth, with full-year revenue reaching $291.8 million, marking a 44% increase and indicating the company's ability to self-fund its strategy and future growth.
- Recorlev Growth Engine: Revenue from Recorlev hit $45.3 million in Q4, with over 100% growth for the year and a doubling of the patient base to approximately 700, as the commercial team was nearly doubled in January to accelerate adoption, showcasing strong market demand and expansion potential.
- Positive Future Outlook: Management projects total revenue for 2026 to be between $375 million and $390 million, representing over 30% growth at the midpoint compared to 2025, while planning to increase R&D spending by $25 million and SG&A by $45 million to support the clinical advancement of XP-8121.
- Patent Protection Measures: The company has filed a patent infringement lawsuit to protect Recorlev, holding four Orange Book-listed patents valid until 2040, demonstrating a commitment to safeguarding its intellectual property and reducing potential competitive risks.
See More
Wall Street's First Trading Day of March Outlook
- Middle East Impact: The U.S.-Israeli attack on Iran is likely to ripple through financial markets, with oil prices rising due to geopolitical risk premiums, as Brent crude has surged from the low $60s to around $73, indicating potential for further volatility.
- CrowdStrike Earnings Preview: CrowdStrike is set to report its quarterly results after Tuesday's close, with Wall Street expecting fiscal 2026 Q4 revenue of $1.3 billion and EPS of $1.10, providing CEO George Kurtz an opportunity to highlight the cybersecurity sector's unique position amidst AI disruption fears.
- Broadcom Earnings Expectations: Broadcom will release its earnings on Wednesday, with anticipated fiscal 2026 Q1 revenue of $19.14 billion and EPS of $2.02, as market sentiment remains optimistic about AI chip demand despite concerns over potential disruptions to infrastructure software.
- Costco Quarterly Report: Costco is expected to report its fiscal 2026 Q2 results after Thursday's close, with projected revenue of $69.22 billion and EPS of $4.56, as management will address consumer spending trends and membership renewal rates amid high price pressures.
See More
Xeris Biopharma Shares Drop Amid Patent Infringement Lawsuit
- Patent Lawsuit Impact: Xeris Biopharma Holdings, Inc. has filed a patent infringement lawsuit against Torrent Pharmaceuticals and Somerset Therapeutics to protect its drug Recorlev, demonstrating the company's commitment to safeguarding its intellectual property rights.
- Stock Price Volatility: Despite a notable 61.30% increase in stock price over the past year, XERS shares are currently trading at $6.01, which is 12.6%, 15.9%, and 20.2% below the 20-day, 50-day, and 100-day moving averages, indicating a bearish sentiment in the short term.
- Technical Indicator Analysis: The current Relative Strength Index (RSI) stands at 42.31, indicating a lack of strong momentum, while the MACD being below the signal line further confirms bearish trends, suggesting that investors should remain cautious about potential shifts in stock trajectory.
- Earnings Outlook: Xeris Biopharma is set to report earnings on March 2, 2026, with an estimated EPS of 4 cents and revenue of $84.17 million, reflecting a positive growth outlook despite the challenges posed by the patent lawsuit.
See More
Xeris Pharmaceuticals to Announce Q4 Earnings on March 2
- Earnings Announcement: Xeris Pharmaceuticals is set to release its Q4 2023 earnings report on March 2 before market open, with a consensus EPS estimate of $0.04, reflecting a significant year-over-year increase of 233.3%, indicating a notable improvement in profitability.
- Revenue Growth Expectations: Analysts forecast that Xeris will achieve $86 million in revenue for Q4, representing a 43.1% year-over-year growth, which highlights the company's strong performance in market demand and product sales, potentially boosting investor confidence.
- Pipeline Opportunities: Xeris Biopharma shows strong momentum with its Recorlev product, indicating potential in drug development and market expansion, which could support future revenue growth.
- Rating Downgrade Impact: Despite the strong growth outlook, Xeris Biopharma's rating has been downgraded, reflecting market caution regarding the company's future performance, which may exert short-term pressure on its stock price.
See More
